JPH0429350B2 - - Google Patents
Info
- Publication number
- JPH0429350B2 JPH0429350B2 JP57173669A JP17366982A JPH0429350B2 JP H0429350 B2 JPH0429350 B2 JP H0429350B2 JP 57173669 A JP57173669 A JP 57173669A JP 17366982 A JP17366982 A JP 17366982A JP H0429350 B2 JPH0429350 B2 JP H0429350B2
- Authority
- JP
- Japan
- Prior art keywords
- fibrin
- effect
- action
- trypsin inhibitor
- methyl ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000000694 effects Effects 0.000 claims description 77
- 102000009123 Fibrin Human genes 0.000 claims description 61
- 108010073385 Fibrin Proteins 0.000 claims description 61
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 61
- 229950003499 fibrin Drugs 0.000 claims description 61
- 102000035195 Peptidases Human genes 0.000 claims description 60
- 108091005804 Peptidases Proteins 0.000 claims description 60
- 239000004365 Protease Substances 0.000 claims description 58
- 229940122618 Trypsin inhibitor Drugs 0.000 claims description 25
- 101710162629 Trypsin inhibitor Proteins 0.000 claims description 25
- 239000002753 trypsin inhibitor Substances 0.000 claims description 25
- 239000000758 substrate Substances 0.000 claims description 20
- 238000010521 absorption reaction Methods 0.000 claims description 12
- 239000005018 casein Substances 0.000 claims description 11
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 11
- 235000021240 caseins Nutrition 0.000 claims description 11
- 230000000593 degrading effect Effects 0.000 claims description 11
- 230000002779 inactivation Effects 0.000 claims description 10
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims description 9
- 108010000912 Egg Proteins Proteins 0.000 claims description 9
- 102000002322 Egg Proteins Human genes 0.000 claims description 9
- 235000014103 egg white Nutrition 0.000 claims description 9
- 210000000969 egg white Anatomy 0.000 claims description 9
- 238000000921 elemental analysis Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 claims description 8
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims description 8
- 108010087765 Antipain Proteins 0.000 claims description 8
- 244000045232 Canavalia ensiformis Species 0.000 claims description 8
- OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 claims description 8
- 244000068988 Glycine max Species 0.000 claims description 8
- 235000010469 Glycine max Nutrition 0.000 claims description 8
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 claims description 8
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 claims description 8
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 claims description 8
- 235000010617 Phaseolus lunatus Nutrition 0.000 claims description 8
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 claims description 8
- 229960002684 aminocaproic acid Drugs 0.000 claims description 8
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 claims description 8
- 108010086192 chymostatin Proteins 0.000 claims description 8
- 238000000354 decomposition reaction Methods 0.000 claims description 8
- DGTVXEHQMSJRPE-UHFFFAOYSA-M difluorophosphinate Chemical compound [O-]P(F)(F)=O DGTVXEHQMSJRPE-UHFFFAOYSA-M 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 8
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 claims description 8
- 108010052968 leupeptin Proteins 0.000 claims description 8
- 108010091212 pepstatin Proteins 0.000 claims description 8
- 229950000964 pepstatin Drugs 0.000 claims description 8
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 claims description 8
- 230000033885 plasminogen activation Effects 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 238000000862 absorption spectrum Methods 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 108010039627 Aprotinin Proteins 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- FKMJXALNHKIDOD-LBPRGKRZSA-N TAMe Chemical compound NC(=N)NCCC[C@@H](C(=O)OC)NS(=O)(=O)C1=CC=C(C)C=C1 FKMJXALNHKIDOD-LBPRGKRZSA-N 0.000 claims description 5
- SRLROPAFMUDDRC-INIZCTEOSA-N ethyl N-benzoyl-L-tyrosinate Chemical compound C([C@@H](C(=O)OCC)NC(=O)C=1C=CC=CC=1)C1=CC=C(O)C=C1 SRLROPAFMUDDRC-INIZCTEOSA-N 0.000 claims description 5
- QRDFLIILGVFYCF-QMMMGPOBSA-N methyl (2s)-2-benzamidopropanoate Chemical compound COC(=O)[C@H](C)NC(=O)C1=CC=CC=C1 QRDFLIILGVFYCF-QMMMGPOBSA-N 0.000 claims description 5
- 229940108519 trasylol Drugs 0.000 claims description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 claims 3
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 claims 1
- FORVAIDSGSLRPX-RGMNGODLSA-N methyl (2s)-2,6-diaminohexanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CCCCN FORVAIDSGSLRPX-RGMNGODLSA-N 0.000 claims 1
- -1 trandiol Chemical compound 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 description 28
- 108090000790 Enzymes Proteins 0.000 description 28
- 229940088598 enzyme Drugs 0.000 description 28
- 239000007864 aqueous solution Substances 0.000 description 20
- 230000003480 fibrinolytic effect Effects 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000000243 solution Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 239000000284 extract Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 102000011632 Caseins Human genes 0.000 description 7
- 108010076119 Caseins Proteins 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000003301 hydrolyzing effect Effects 0.000 description 6
- 241000361919 Metaphire sieboldi Species 0.000 description 5
- 102000013566 Plasminogen Human genes 0.000 description 5
- 108010051456 Plasminogen Proteins 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000000691 measurement method Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 241001233061 earthworms Species 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DGZSVBBLLGZHSF-UHFFFAOYSA-N 4,4-diethylpiperidine Chemical compound CCC1(CC)CCNCC1 DGZSVBBLLGZHSF-UHFFFAOYSA-N 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010038061 Chymotrypsinogen Proteins 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- 241001495098 Lumbricus rubellus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000034698 Vitreous haemorrhage Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002159 anterior chamber Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010421 standard material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57173669A JPS5963184A (ja) | 1982-10-02 | 1982-10-02 | 新規なプロテア−ゼ |
| AU16293/83A AU1629383A (en) | 1982-10-02 | 1983-06-27 | Earthworm tissue protease thrombolytic agents |
| US06/508,163 US4568545A (en) | 1982-10-02 | 1983-06-27 | Thrombolytic agent |
| EP83106288A EP0105092A3 (en) | 1982-10-02 | 1983-06-28 | A thrombolytic agent |
| CA000431387A CA1198697A (en) | 1982-10-02 | 1983-06-28 | Thrombolytic agent |
| FI832383A FI832383L (fi) | 1982-10-02 | 1983-06-29 | Trombosytiskt aemne |
| DK300883A DK300883A (da) | 1982-10-02 | 1983-06-29 | Fremgangsmaade til fremstilling af thrombolytiske midler |
| KR1019830002990A KR840006438A (ko) | 1982-10-02 | 1983-06-30 | 혈전용해제 |
| ES523754A ES8504246A1 (es) | 1982-10-02 | 1983-06-30 | Un metodo para la preparacion de las proteasas fibrinoliticamente activas |
| NO832399A NO832399L (no) | 1982-10-02 | 1983-06-30 | Trombolytisk middel |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57173669A JPS5963184A (ja) | 1982-10-02 | 1982-10-02 | 新規なプロテア−ゼ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5963184A JPS5963184A (ja) | 1984-04-10 |
| JPH0429350B2 true JPH0429350B2 (ko) | 1992-05-18 |
Family
ID=15964899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57173669A Granted JPS5963184A (ja) | 1982-10-02 | 1982-10-02 | 新規なプロテア−ゼ |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPS5963184A (ko) |
| KR (1) | KR840006438A (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR890004724A (ko) * | 1987-09-17 | 1989-05-09 | 히사시 미하라 | 신규 프로테아제 제제(製劑) |
| JP2006096673A (ja) * | 2004-09-28 | 2006-04-13 | Mihara Lr Kenkyusho:Kk | ミミズ製品の製造方法 |
-
1982
- 1982-10-02 JP JP57173669A patent/JPS5963184A/ja active Granted
-
1983
- 1983-06-30 KR KR1019830002990A patent/KR840006438A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5963184A (ja) | 1984-04-10 |
| KR840006438A (ko) | 1984-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hooper et al. | Isolation of two differentially glycosylated forms of peptidyl-dipeptidase A (angiotensin converting enzyme) from pig brain: a re-evaluation of their role in neuropeptide metabolism | |
| DK166587B1 (da) | Blodkoagulationshaemmende proteiner, fremgangsmaade til deres fremstilling samt deres anvendelse | |
| US5849560A (en) | Proteases causing degradation of amyloid β-protein precursor | |
| US4568545A (en) | Thrombolytic agent | |
| JPS6254286B2 (ko) | ||
| Yoshioka et al. | Role of rat intestinal brush-border membrane angiotensin-converting enzyme in dietary protein digestion | |
| JPH0710880B2 (ja) | 抗血液凝固物質、その製法及びそれを有効成分とする抗血液凝固剤 | |
| US3849252A (en) | Enzyme composition and process for the manufacture thereof | |
| Ouyang et al. | Physicochemical properties of α-and β-fibrinogenases of Trimeresurus mucrosquamatus venom | |
| Majumdar et al. | Antiplatelet and antithrombotic activity of a fibrin (ogen) olytic protease from Bacillus cereus strain FF01 | |
| JPH0567278B2 (ko) | ||
| Zolfaghari et al. | A high-molecular-mass neutral endopeptidase-24.5 from human lung | |
| AU659807B2 (en) | Platelet adhesion inhibitor | |
| US5831025A (en) | Human activated protein C and process for preparing same | |
| CA1256027A (en) | Fibrinophilic urokinase complex and method for production thereof | |
| JPS6130527A (ja) | 血栓溶解剤 | |
| JPH0429350B2 (ko) | ||
| JPS6147511B2 (ko) | ||
| KR100377279B1 (ko) | 트롬빈의제조방법 | |
| Nagasawa et al. | A simple method for purification of bovine plasminogen | |
| Váradi et al. | Purification and properties of human factor IXa | |
| US6803038B1 (en) | Use of bromelaine proteases for inhibiting blood coagulation | |
| JPS6396132A (ja) | 抗血液凝固物質及びその製法 | |
| JP3810439B2 (ja) | トロンビンの製造法 | |
| JP3878668B2 (ja) | 血栓性疾患の治療 |